Inhibitors of mycobacterial efflux pumps as potential boosters for anti-tubercular drugs.

Authors: Ainsa J, Amaral L, Couto I, Machado D, Martins M, Rodrigues L, Viveiros M
Journal: Expert Review of Anti-infective Therapy
Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Inhibitors+of+mycobacterial+efflux+pumps+as+potential+boosters+for+anti-tubercular+drugs

Tuberculosis is one of the major causes of infection across the world. The emergence of multi-, extensively- and totally drug-resistant strains of Mycobacterium tuberculosis contributes to the lack of therapeutic options available.
Read More

Why and how thioridazine in combination with antibiotics to which the infective strain is resistant will cure totally drug-resistant tuberculosis.

Over a period of 14 years, the authors have studied thioridazine, an old neuroleptic, that has been shown to have in vitro activity against intracellular Mycobacterium tuberculosis, regardless of its antibiotic resistance status, thioridazine cures infected mice of antibiotic-susceptible and multidrug-resistant tuberculosis (TB) infections and, when used in combination with antibiotics used for therapy of TB, renders the organism significantly more susceptible.
Read More

Inhibitors of mycobacterial efflux pumps as potential boosters for anti-tubercular drugs.

Why and how thioridazine in combination with antibiotics to which the infective strain is resistant will cure totally drug-resistant tuberculosis.

About GHTM

Contacts

Funding